[Etiotropic therapy of chronic bacterial prostatitis].
A total of 20 patients entered the clinical trial of efficacy and safety of Russian produced drug levofloxacin (floracid) in the treatment of chronic bacterial prostatitis (CBP). The drug was given in a single dose of 500 mg/day for 28 days. Antibacterial treatment of CBP with floracid killed sensitive to it bacteria in 18 of 20 (90%) CBP patients. Symptoms of the disease attenuated including pain syndrome and voiding disorders, quality of life assessed by NIH-CPSI scale improved. The absence of side effects points to good tolerance and safety of the drug.
Popov
S V
SV
Mazo
E B
EB
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011788:Quality of Life; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin